Trillium Therapeutics Appoints Michael Kamarck, Ph.D., to Its Board of Directors
September 18 2020 - 7:00AM
Trillium Therapeutics Inc. (“Trillium” or the “Company”)
(NASDAQ/TSX: TRIL), a clinical stage immuno-oncology
company developing innovative therapies for the treatment of
cancer, today announced the appointment of pharmaceutical industry
leader Michael Kamarck, Ph.D., to its Board of Directors, effective
immediately.
“We are excited to welcome Dr. Kamarck to the
board of directors,” said Robert L. Kirkman, M.D., Chair of
Trillium Therapeutics. “His long experience and
expertise with the development and manufacturing of biologic
products will be of particular value as Trillium is preparing to
scale up its clinical development activities, with multiple phase 2
programs expected to start next year.”
Dr. Kamarck has significant expertise in
biologics manufacturing and a breadth of management and technical
experience, having served in senior leadership positions at a
number of leading pharmaceutical companies during a career that
spans over 25 years. He currently serves as Chief Technology
Officer for Vir Biotechnology, Inc., where he manages a
multi-modality technical approach to the development of treatments
for serious infectious diseases such as COVID-19, influenza and
hepatitis B.
“I am honored to join Trillium’s Board and look
forward to contributing my knowledge in pharmaceutical research,
technical operations and biologics manufacturing as the company
advances towards clinical and commercial success,” said Dr.
Kamarck. “This is truly an exciting time for Trillium, which is
well positioned to become a leading player in the CD47 field, with
a unique pipeline of two differentiated agents that are showing
best-in-class potential.”
Before joining Vir, Dr. Kamarck was Senior Vice
President of Global Vaccines and Biologics Manufacturing and
President of Merck BioVentures where he was instrumental in
establishing Merck’s global biosimilars business. Prior to Merck,
Dr. Kamarck held various senior executive positions at Wyeth
Pharmaceuticals, including President, Technical Operations and
Product Supply, and was responsible for establishing a global
biotechnology network with $3.5 billion of capital investment to
manufacture several blockbuster products, including Enbrel
(etanercept). He began his pharmaceutical career at Bayer serving
in numerous roles in research and technical operations, including
Senior Vice President of Operations for Bayer Biologicals.
Dr. Kamarck received his B.A. from Oberlin
College, his Ph.D. in biochemistry from Massachusetts Institute of
Technology and was a Leukemia Society Fellow at Yale University. He
has authored more than 50 peer-reviewed publications and has 20
issued patents.
About Trillium Therapeutics
Trillium is an immuno-oncology company
developing innovative therapies for the treatment of cancer. The
company’s two clinical programs, TTI-621 and TTI-622, target
CD47, a “don’t eat me” signal that cancer cells frequently use to
evade the immune system.
For more information visit:
www.trilliumtherapeutics.com
Caution Regarding Forward-Looking
Information
This press release contains forward-looking
statements within the meaning of applicable United States
securities laws and forward-looking information within the meaning
of Canadian securities laws (collectively, "forward-looking
statements"). Forward-looking statements in this press release
include statements about, without limitation, the expected timing
of the release of further data on Trillium’s TTI-621 and TTI-622
studies and the belief that Trillium’s programs could achieve
best-in class status. With respect to the forward-looking
statements contained in this press release, Trillium has made
numerous assumptions regarding, among other things: the impact of
the Covid-19 pandemic on its operations, the effectiveness and
timeliness of preclinical and clinical trials; and the
completeness, accuracy and usefulness of the data. While Trillium
considers these assumptions to be reasonable, these assumptions are
inherently subject to significant scientific, business, economic,
competitive, market and social uncertainties and contingencies.
Additionally, there are known and unknown risk factors that could
cause Trillium's actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements
contained in this press release. A discussion of risks and
uncertainties facing Trillium appears in Trillium's Annual
Information Form for the year ended December 31, 2019 filed with
Canadian securities authorities and on Form 40-F with the U.S.
Securities Exchange Commission, each as updated by Trillium's
continuous disclosure filings, which are available at
www.sedar.com and at www.sec.gov. All forward-looking
statements herein are qualified in their entirety by this
cautionary statement, and Trillium disclaims any obligation to
revise or update any such forward-looking statements or to publicly
announce the result of any revisions to any of the forward-looking
statements contained herein to reflect future results, events or
developments, except as required by law.
Investor Relations:James ParsonsChief Financial
OfficerTrillium Therapeutics Inc. 416-595-0627
x232james@trilliumtherapeutics.com www.trilliumtherapeutics.com
Media Relations:Mike Beyer Sam Brown Inc.
312-961-2502mikebeyer@sambrown.com
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Sep 2023 to Sep 2024